SORILUX (calcipotriene) by Molecular Devices is clinical pharmacology in humans, the natural supply of vitamin d depends mainly on exposure to the ultraviolet rays of the sun for conversion of 7-dehydrocholesterol to vitamin d 3 (cholecalciferol) in the skin. Approved for psoriasis. First approved in 2010.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
SORILUX is a topical vitamin D analog foam formulation of calcipotriene approved for psoriasis and acne vulgaris. It works by mimicking the active form of vitamin D (calcitriol), regulating skin cell proliferation and differentiation to reduce inflammatory plaques. Approximately 6% of the applied dose is systemically absorbed, with rapid metabolism to inactive metabolites.
Product is approaching loss of exclusivity with minimal Medicare spending, suggesting a small, declining commercial team focused on managed care and dermatology channels.
CLINICAL PHARMACOLOGY In humans, the natural supply of vitamin D depends mainly on exposure to the ultraviolet rays of the sun for conversion of 7-dehydrocholesterol to vitamin D 3 (cholecalciferol) in the skin. Calcipotriene is a synthetic analog of vitamin D 3 . Clinical studies with…
Vitamin D Analog
Worked on SORILUX at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
A Study to Assess Treatment Satisfaction, Patient-reported Outcomes, Effectiveness, and Safety of a Fixed-dose Combination of Calcipotriene/Betamethasone Dipropionate PAD Cream in the Treatment of Mild-to-moderate Plaque Psoriasis of the Scalp in Adults
BE Study of Calcipotriene Hydrate and Betamethasone Dipropionate Topical Suspension in the Treatment of Scalp Psoriasis
An Observational Study to Assess Patient Satisfaction and Control of Psoriasis With Calcipotriene/Betamethasone Dipropionate (Taclonex®) Topical Suspension, and Effect on Quality of Life
Evaluate Safety and Tolerability of Calcipotriene Foam 0.005% in Pediatric Subjects With Mild/Moderate Plaque Psoriasis
Olux E Foam and Sorilux Foam Combination Therapy for the Maintenance of Treatment Response in Patients With Moderate Plaque Psoriasis
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moLOE in ~3 years — strategic planning for patent cliff underway
SORILUX shows minimal linked job postings, reflecting its small commercial footprint and declining market relevance in a landscape dominated by systemic therapies. Roles on this franchise are likely limited to regional dermatology specialists and managed care account managers at Molecular Devices.